login about | contact | download material | search | disclaimer
immunosigns Antibodies ImmunoAssays Diagnostics
Analytical methods Consultancy Project Management
R & D Services Training References
>> News
ImmunoSigns
> 2010-08-26
Bioluminescent recombinant IC2 developed in collaboration with Stanford University
> 2010-08-26
IC2 expected on the international market from 2011.
> 2010-08-26
Preliminary biodistribution studies done in mice and rats
> 2010-08-26
In the search for the autoantigenic epitope for IC2 - is sulfatid CD1d complexes the target?
> 2010-08-26
The basic and clinical related research concerning IC2 and its autoantigen move from the Panum Institute, Department of Biomedical Sciences, to the new modern Copenhagen Biocenter at The Bartholin Institute
> 2010-08-26
Antibody-online.com negotiation for contracting marketing and sale.
> 2010-08-26
Large scale production of the genuin native IC2 monoclonal autoantibody has been initiated on contract with the Chech Republic biotech EXBIO.
> 2010-08-26
The EU-Fasilis programme supporting SME Biotech collaboration has granted ImmunoSigns with a Voucher .
> 2010-08-26
Recombinant chimeric humanised rhIC2-IgG
ImmunoSigns

ImmunoSigns is a Biotech company founded in 1996. We offer you help in project management and R&D activities within biotechnology and immunodetection.

ImmunoSigns offers conferences, courses and individual professional training in project planning, fundraising, strategic project management, risk analysis, and contingency planning.

Consultancy is given for patent, license, royalty and IPR management. Coaching and supervision of R&D projects including technical aids support and fasten your discoveries. 

Print this page / Carl-Henrik Brogren (chb@immunosigns.com) / 2006-11-07

 
Immunosigns • Henningsens Allé 38 • DK 2900 Hellerup • Tel.: +45 2041 6249 • Fax: +45 3962 2247 • info@immunosigns.com